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Abstract
Background:  It has been recently reported that major pathogens Staphylococcus aureus and
Pseudomonas aeruginosa accelerate a normal process of cell surface syndecan-1 (Synd1) ectodomain
shedding as a mechanism of host damage due to the production of shedding-inducing virulence
factors. We tested if acceleration of Synd1 shedding takes place in vitro upon treatment of epithelial
cells with B. anthracis hemolysins, as well as in vivo during anthrax infection in mice.
Results: The isolated anthrax hemolytic proteins AnlB (sphingomyelinase) and AnlO (cholesterol-
binding pore-forming factor), as well as ClnA (B. cereus homolog of B. anthracis phosphatidyl
choline-preferring phospholipase C) cause accelerated shedding of Synd1 and E-cadherin from
epithelial cells and compromise epithelial barrier integrity within a few hours. In comparison with
hemolysins in a similar range of concentrations, anthrax lethal toxin (LT) also accelerates shedding
albeit at slower rate. Individual components of LT, lethal factor and protective antigen are inactive
with regard to shedding. Inhibition experiments favor a hypothesis that activities of tested bacterial
shedding inducers converge on the stimulation of cytoplasmic tyrosine kinases of the Syk family,
ultimately leading to activation of cellular sheddase. Both LT and AnlO modulate ERK1/2 and p38
MAPK signaling pathways, while JNK pathway seems to be irrelevant to accelerated shedding.
Accelerated shedding of Synd1 also takes place in DBA/2 mice challenged with Bacillus anthracis
(Sterne) spores. Elevated levels of shed ectodomain are readily detectable in circulation after 24 h.
Conclusion: The concerted acceleration of shedding by several virulence factors could represent
a new pathogenic mechanism contributing to disruption of epithelial or endothelial integrity,
hemorrhage, edema and abnormal cell signaling during anthrax infection.
Background
It has been recently reported that major pathogens Staphy-
lococcus aureus and Pseudomonas aeruginosa exploit acceler-
ation of syndecan (Synd) ectodomain shedding as a
mechanism of host damage and thus increase their viru-
lence [1-3]. Approximately 1% of cell surface proteins are
thought to be shed into the extracellular environment by
host cells as a process of normal cell surface turnover [4],
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however during the infectious process shedding can reach
pathological proportions. The diverse list of proteins,
which are normally shed from the cell surface includes but
is not limited to cytokines, growth factors, and cell adhe-
sion molecules, such as tumor necrosis factor (TNFα),
transforming growth factor α (TGFα), epidermal growth
factors (EGFs), L-selectin, CD44, and Synds [[5] and cita-
tions within].
Synds are a group of four distinct proteoglycans (PGs),
containing transmembrane core proteins modified with
several heparan sulfate (HS) and chondroitin sulfate
chains. Synd1 is the major HS PG of epithelial cells, which
binds and regulates a wide variety of biological molecules
through its HS chains [6]. Syndecans act as adhesion mol-
ecules, modulators of growth factor function, and co-
receptors in processes as diverse as morphogenesis, tissue
repair, host defense, tumor development, and energy
metabolism. In mammary epithelial cells Synd1 co-local-
izes with actin filaments thus anchoring the cytoskeleton
to extracellular matrix. Synd4 can be found in the focal
adhesion junctions between cells [7]. Therefore, Synds are
involved in modulation of cell spreading, adhesion,
motility and maintenance of intercellular contacts. Ecto-
domain shedding rapidly changes the surface phenotype
of affected cells and generates soluble, biologically active
ectodomains that can function as paracrine or autocrine
effectors. A growing body of evidence indicates that these
molecular and cellular features enable ectodomain shed-
ding to regulate many pathophysiological processes, such
as microbial pathogenesis, inflammation, and tissue
repair [1,8].
Shedding of syndecans can be abnormally increased in
the case of the infectious process. The P. aeruginosa shed-
ding enhancer was identified as LasA, a known metallo-
protease virulence factor [1]. Studies in vivo indicate that
P. aeruginosa activates Synd1 shedding to enhance its vir-
ulence in a murine model of lung infection [2]. Shedding
enhancers of S. aureus are represented by pore-forming α-
toxin and sphingomyelinase β-toxin [3]. During the infec-
tious process, proteolytic removal of ectodomain in a sol-
Synd1 shedding from NMuMG cells after treatment with B. anthracis proteins in the presence of 1% FCS for 4 h (24 h in the  case of LT, PA and LF) Figure 1
Synd1 shedding from NMuMG cells after treatment with B. anthracis proteins in the presence of 1% FCS for 4 h (24 h in the 
case of LT, PA and LF). The lower right panel shows cell death measured after 4 h as LDH release for untreated cells (1), 1 µg/
ml ClnA (2), 1 µg/ml AnlB (3), 0.1 µg/ml AnlO (4), untreated cells after 24 h (5), 1 µg/ml LT after 24 h (6). Error bars represent 
95% confidence intervals (n = 6).
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uble form by secreted microbial factors could enhance
host colonization by altering the morphology and com-
promising the integrity of protective barriers formed by
polarized epithelial cells of the skin, the surfaces of body
cavities and internal organs, as well as endothelial cells
lining blood vessel walls. The initial pathology can be fur-
ther aggravated by exposing intercellular, basolateral, and
subepithelial adhesive components to bacterial factors
[9]. Structural damage to the host cell surface with result-
ing insult to protective barriers caused by ectodomain
shedding along with pathological signaling can initiate a
mechanism ultimately leading to the malfunction and
failure of life-critical organs and systems.
Inhalation anthrax is a systemic disease characterized by
severe damage to epithelia residing in major internal
organs such as the liver, lung, intestines, spleen, and kid-
neys. Disruption of vasculature resulting in massive hem-
orrhages and pleural edema is a hallmark of systemic
anthrax [10-12]. The B. anthracis genome contains genes
for several proteolytic and hemolytic factors, which are
structurally similar to the shedding inducers from P. aeru-
ginosa and S. aureus, including among others the S. aureus
α- and β-toxin homologues: anthralysin O (AnlO, pore-
forming cholesterol-dependent hemolysin) and anthra-
lysin B (AnlB, sphingomyelienase), respectively [13,14].
Another anthrax hemolytic factor of interest regarding its
potential activity in ectodomain shedding is anthralysin A
(AnlA, phosphatidyl choline-preferring phospholipase C,
PC-PLC), which is 99% homologous to its B. cereus coun-
terpart, cereolysin A (ClnA) [13]. Johansen et al. [15]
reported that NIH 3T3 cells stably transfected with the
gene encoding ClnA displayed a transformed phenotype.
Exogenously applied ClnA decreased cell-cell contacts and
increased cell migration [16]. Despite these observations
the ectodomain shedding has never been studied with
regard to infections caused by B. anthracis or B. cereus.
Therefore, the main goal of this study was to test our
hypothesis regarding the shedding activity of B. anthracis
hemolytic proteins and to demonstrate that Synd ectodo-
main shedding takes place in response to anthrax infec-
tion.
In addition to the hemolysins our attention was attracted
to the lethal toxin (LT), a major anthrax virulence factor
[17]. The mediator(s) of its toxicity remains unknown. It
has been shown that LT abrogates intracellular signaling
through proteolytic cleavage of mitogen-activated protein
kinase kinases (MAPKK) [18]. Administration of lethal
doses of a purified LT to mice and rats causes pleural
edema [19] indicating that LT compromises the integrity
of intercellular contacts maintaining the fluid homeosta-
sis in the lung. It has been previously suggested that LT is
capable of increasing vascular permeability [20], and
recent experiments with endothelial cells in culture are
consistent with this conclusion [21]. Therefore, we
Western blot of Synd1 shed from NMuMG cells by B. anthra- cis proteins in presence of 1% FCS for 24 h Figure 3
Western blot of Synd1 shed from NMuMG cells by B. anthra-
cis proteins in presence of 1% FCS for 24 h. Synd1 from cul-
ture supernatants was partially purified using DEAE ion 
exchange chromatography and analyzed before (lanes 1 to 4) 
and after (lanes 5 to 8) partial digestion for 5 h with both 
heparanase II (10 mU/ml) and chondroitin sulfate ABC lyase 
(20 mU/ml) to remove glycosaminoglycan chains. For diges-
tion the amount of total protein in each reaction was 
adjusted approximately equal. Gel lanes correspond to 
untreated cells (1, 5) and cells challenged with: 0.1 µg/ml of 
AnlO for 4 h (2, 6); 1 µg/ml of AnlB for 4 h (3, 7); 1 µg/ml of 
LT for 24 h (4, 8). Synd1 core protein appears as a band of 
approximately 80 kD (open arrow).
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Time course of Synd1 release from NMuMG cells transferred  into 1% FCS media and challenged with 1 µg/ml of either  AnlO (triangles), or LT (squares) Figure 2
Time course of Synd1 release from NMuMG cells transferred 
into 1% FCS media and challenged with 1 µg/ml of either 
AnlO (triangles), or LT (squares). Control cells were left 
untreated (circles). Each measurement corresponds to aver-
age of three culture wells. Three independent experiments 
have been performed with similar results.
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wanted to test whether LT can function as a shedding
inducer, and whether the inhibition of MAPKKs by LT
modulates cell signaling relevant to shedding.
In the current study, we report characterization of the iso-
lated anthrax hemolytic proteins AnlO, AnlB, as well as
the AnlA homolog ClnA from B. cereus, regarding their
Immunohistochemical detection of E-cadherin in monolayers of NMuMG cells after treatment with LT and hemolytic proteins  (1 µg/ml each for 16 h) Figure 4
Immunohistochemical detection of E-cadherin in monolayers of NMuMG cells after treatment with LT and hemolytic proteins 
(1 µg/ml each for 16 h). Nuclei are stained blue with DAPI, and E-cadherin is stained green with FITC-conjugated anti-E-cad-
herin antibody. In the case of AnlO and AnlB, arrows indicate some of the most damaged areas. 40× magnification.
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Synd shedding and barrier permeability-enhancing activi-
ties. We found that LT also stimulates Synd1 shedding
(although to a less extent compared to hemolysins) by the
mechanism which involves the MAPKK signaling path-
ways. Overall, our observations identify a novel strategy of
anthrax virulence factors, which among their diverse bio-
chemical activities stimulate the host cell stress responses
ultimately leading to activation of the ectodomain shed-
ding. In connection with these observations we also dem-
onstrate that Synd1 shedding occurs during the infectious
process in the B. anthracis (Sterne) spore-challenged mice.
The elevated levels of shed Synd1 are readily detectable in
the circulation just 24 h post challenge. This new feature
of the anthrax infectious process could be of high patho-
genic significance. We suggest that a cumulative effect of
several virulence factors on ectodomain shedding could
compromise the integrity of host protective barriers, cause
malfunction of major organs, and ultimately contribute to
the pathological systemic response typical in anthrax
patients.
Results
Hemolytic factors and LT increase ectodomain shedding 
from normal murine mammary gland (NMuMG) epithelial 
cells
Shedding activity of isolated recombinant proteins identi-
fied by us as candidate shedding inducers was tested using
NMuMG epithelial cells. This murine cell type represents
a commonly used model in similar studies [3]. Synd1 is
abundant on the epithelial cells and can be assayed using
antibodies specific to the corresponding core proteins or
the HS chains. Using immunodetection with antibodies
specific for Synd1 core protein we tested NMuMG cell cul-
ture supernatants for the presence of soluble Synd1 in the
assay conditions when highly charged HS chains are selec-
tively retained by the blotting membrane. We found that
all tested hemolytic proteins, namely AnlO, AnlB and
ClnA, as well as LT cause a concentration-dependent
acceleration of Synd1 release into culture supernatants
albeit at significantly different amounts (Fig. 1). The time
course of Synd1 release in the case of AnlO shows a fast
increase in the amount of shed Synd which continues for
several hours (Fig. 2). The LT causes increase in Synd1
shedding, although the effect of LT is of lower intensity
and develops slower compared to AnlO. The individual
components of LT, the protective antigen (PA) and the
lethal factor (LF) do not induce shedding (Fig. 1). This
suggests that neither the extracellular enzymatic activity of
LF nor the sole pore-forming capacity of PA is directly
responsible for shedding.
Analysis of cell viability in the shedding experiments
reveals a marginal to small degree of the lactate dehydro-
genase (LDH) release from treated cells compared to
untreated ones. There is no obvious correlation of cell
death with the amount of shed Synd1, which allows us to
conclude that the processes of shedding and cell death are
not directly related to each other but rather take place con-
comitantly, depending on the nature of the pathogenic
factor and other treatment conditions. For example, treat-
ments with either ClnA or AnlB presented in Fig. 1 are not
cytolytic, while the amounts of shed Synd1 in both cases
increase 8-fold. AnlO increases cell death 3-fold (from 2%
to 6%), while there is an 11-fold increase in Synd1 shed-
ding. In the case of LT, incubation for 24 h leads to a 1.6-
fold increase in cell death (from 10% to 16%), while the
amount of shed Synd1 increases almost 3-fold. The above
conclusion agrees with direct microscopic observation of
treated monolayers displaying live cells with partially or
completely shed Synd1 detected by fluorescently-labeled
anti-Synd1 antibodies (see below). We did not explore
this topic further, however available data show that the E-
cadherin shedding preceded apoptosis in enterocytes
[22], while in endothelial cells LT compromised the bar-
rier integrity (presumably through ectodomain shedding)
independently of apoptosis or necrosis [21]. Stimulation
with the phorbol ester, PMA, a known inducer of shed-
ding [5], prolonged viability of epithelial cells [23] and
predisposed monocytes to apoptotic death caused by LT
[24].
In order to confirm the biochemical identity of shed
Synd1, the following experiment has been carried out.
Western blot of NMuMG cell supernatants after treatment
with either AnlO, AnlB or LT using anti-mouse Synd1
antibody demonstrates a high molecular mass smear
band that can be attributed to the presence of heterogene-
ous heparan sulfate glucosaminoglycan chains in shed
Synd1 (Fig. 3). Indeed, digestion of the supernatants with
heparanase II and chondrotin sulfate ABC lyase leads to
the appearance of a single band corresponding in gel
mobility to the core Synd1 protein, which typically
migrates in a gel as an approximately 80 KD band [3].
Immunostaining of the NMuMG monolayers with 
fluorescently-labeled antibodies against E-cadherin and 
Synd1
We examined the NMuMG cells grown on glass slides
using immuno-fluorescence microscopy. After challenge
with proteins causing Synd1 shedding the cells were fluo-
rescently stained using E-cadherin- and Synd1-specific
FITC-conjugated monoclonal antibodies. E-cadherin is a
major transmembrane component of the apical junc-
tional complex. In a simple polarized epithelium the
junctional complex consists of tight junctions and under-
lying adherens junctions playing a key role in the forma-
tion and maintenance of epithelial barriers [25]. We
therefore wanted to see if the process of Synd ectodomain
shedding observed in our experiments is accompanied by
the loss of intercellular contacts reflected in the dissocia-BMC Microbiology 2006, 6:8 http://www.biomedcentral.com/1471-2180/6/8
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Immunohistochemical detection of Synd1 in monolayers of NMuMG cells after treatment with LT and hemolytic proteins (1  µg/ml each for 16 h) Figure 5
Immunohistochemical detection of Synd1 in monolayers of NMuMG cells after treatment with LT and hemolytic proteins (1 
µg/ml each for 16 h). Nuclei are stained blue with DAPI, and Synd1 is stained green with FITC-conjugated anti-Synd1 antibody. 
40× magnification.
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UntreatedBMC Microbiology 2006, 6:8 http://www.biomedcentral.com/1471-2180/6/8
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tion of the junctional complex. Our analyses revealed
obvious cytopathogenic changes in treated NMuMG cells.
In all cases, a network of E-cadherin visible in untreated
confluent cells becomes either disorganized, damaged or
disappears from intercellular contacts upon treatment
(Fig. 4), similar to what has been reported for VE-cadherin
in endothelial cells treated with LT [21]. Partially conflu-
ent NMuMG cells demonstrate intensive Synd1 staining
along the perimeter of cells, which partially or completely
disappears from cell surfaces after incubation with the
shedding-inducing proteins, while remnants of the ecto-
domain remain visible in the intercellular space (Fig. 5).
Notably, the treated cells retain a high intensity of DAPI
blue fluorescence typical for undamaged nuclei, indicat-
ing that the loss of E-cadherin and Synd1 takes place from
viable cells.
Inhibition of Synd1 release
The ectodomain shedding of cell surface molecules is typ-
ically mediated by host metalloproteinase sheddases
[5,26]. Both constitutive and accelerated shedding are
inhibited by a variety of substances active in a number of
receptor- and stress-activated signaling pathways, which
involve protein tyrosine kinases (PTKs), protein kinase C
(PKC), and mitogen-activated protein kinases (MAPKs)
[3,5,26]. The activity of LT in macrophages and epithelial
cells has been previously reported to involve down regu-
lation of MAPK kinase cascades [18,23].
The results of inhibition experiments are presented in the
Table. It shows that piceatannol, a specific inhibitor of the
Syk family of PTKs [27] is active in both spontaneous and
induced Synd1 shedding for all tested proteins. In the case
of AnlO and LT at low concentration of 0.5 µM the inhib-
itor shows some stimulatory effect on both constitutive
and induced shedding, but it strongly inhibits Synd1
release in concentrations typical for its activity range of 5
to 50 µM [28]. The effect of piceatannol suggests that all
four factors stimulate signaling pathways, which most
probably involve cytoplasmic Syk, however piceatannol
has also been reported to inhibit other tyrosine kinases in
a similar concentration range. In agreement with the
above suggestion the inhibitor of Src PTK family PP2 is
completely inactive (data not shown). A general PTK
inhibitor tyrphostin A25 (at 0.5 to 5 µM) shows only a
weak activity. The phosphatidylinositol-3-kinase inhibi-
tor LY294002 is inactive with all tested proteins, and we
conclude that the cell survival pathway mediated by this
kinase is irrelevant to shedding.
Suramin is a multi-potent therapeutic [29], which among
other activities displays an antitumoral effect by blocking
the growth factors binding to several receptors, including
the ones for epidermal growth factor (EGF), platelet
derived growth factor (PGDF), insulin growth factor II,
and transforming growth factor-β (TGF-β). These growth
factors bind to heparan sulfate-containing proteoglycans,
which can be shed in various pathophysiological proc-
esses, such as wound repair, and microbial infections
[26,30]. Most importantly, suramin modulates activity of
protein tyrosine phosphatases (PTPs) involved in cell
adhesion, integrin signaling and cell cycle progression
[31,32]. Among these, PTP1B and Cdc25A are inhibited
by suramin in the low µM range. The drug activates PTPα
and PTP LAR at higher concentrations. Because of low bio-
availability, the suramin concentration above 50 µM has
to be used for the activation effect [33]. The Table shows
that similar to piceatannol, suramin stimulates shedding
at 20 µM. At higher concentration, suramin effectively
inhibits Synd1 shedding in NMuMG cells induced by LT
and AnlO. This effect is consistent with the inhibition-
activation pattern of suramin activity toward PTPs, but the
multi-potency of suramin excludes its clear interpretation
without additional studies. Shedding activities of lipases
ClnA and AnlB are insensitive to suramin at all concentra-
tions tested.
In order to understand which signaling pathways among
p38, ERK and JNK are involved in LT-mediated accelera-
tion of Synd shedding, we tested SB202190, an inhibitor
of p38; PD98059, an inhibitor of MEK1/2 (ERK pathway);
and the JNK inhibitor II. While both AnlO and LT induce
Synd1 shedding, LT on itself is a known inhibitor of
MAPK signaling. In contrast, AnlO was reported to stimu-
late p38 in macrophages [34]. We found that the p38
inhibitor in the range of 1 to 10 µM decreased Synd1
shedding in NMuMG cells induced by either AnlO or LT
to the level of spontaneous shedding observed in cultures
without treatment, but it is inactive with ClnA and AnlB.
The inhibitor of ERK pathways PD 98059 (at 5 to 50 µM)
behaves similar to SB202190 with AnlO, but it is less
effective in the LT-induced shedding. The only statistically
reliable effect of the JNK inhibitor is the slight increase in
spontaneous shedding from untreated cells. None of the
tested inhibitors is toxic to cells in the conditions of the
inhibitor experiments (viability of inhibitor-treated con-
trol cells remains at the level above 90%, data not shown)
indicating that activity of tested inhibitors is not depend-
ent on their cytotoxic effect.
Collectively, the inhibition experiments demonstrate that
B. anthracis pathogenic factors induce Synd1 shedding
through different signaling pathways, which seem to con-
verge on activation of cytoplasmic PTKs. Among tested
proteins, one can preliminarily identify two groups of
shedding inducers. The first one includes LT and pore-
forming AnlO influencing MAPK pathways, which are
commonly activated in response to receptor stimulation
and stress, while the other consists of membranolytic
lipases ClnA and AnlB.BMC Microbiology 2006, 6:8 http://www.biomedcentral.com/1471-2180/6/8
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AnlO and LT cause transient phosphorylation of ERK1/2 and p38 in NMuMG epithelial cells Figure 6
AnlO and LT cause transient phosphorylation of ERK1/2 and p38 in NMuMG epithelial cells. Cells were transferred into 
growth media with 1% FCS, treated with indicated concentrations of either AnlO or LT for different periods of time and lysed. 
Western blots were probed with phosphorylation-specific antibodies against ERK1/2 and p38. Results from control untreated 
cells are shown in the AnlO panel.
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ERK1/2 and p38 phosphorylation patterns in NMuMGs 
treated with AnlO or LT
Since both PD98059 and SB202190 influence the AnlO-
and LT-induced Synd1 shedding, ERK1/2 and p38 phos-
phorylation patterns were studied in more detail. Fig. 6
shows that, compared with untreated cells, within several
minutes the AnlO causes a strong transient ERK1/2 activa-
tion lasting for more than 4 h in the presence of 1 µg/ml
AnlO. A lower concentration of AnlO causes a shorter
period of activation followed by a slight increase in sign-
aling after 4 h. The latter is present in both control and
treated cells and probably reflects a distress caused by
incubation in low FCS media. The p38 phosphorylation
reaches maximum intensity after the ERK1/2. In the same
conditions, LT also causes transient activation signals but
its effect on the amounts of activated ERK1/2 and p38 is
different from that of AnlO: the up-regulation of ERK1/2
phosphorylation is detectable at the 10 min time point
and then completely disappears within 30 min. While the
transient peak of p38 activation is detectable at 0.1 µg/ml
of LT, its level remains lower compared to AnlO. As a con-
trol, LT (1 µg/ml) boiled for 15 min is inactive in MAPK
activation (not shown). It seems that the enzymatic cleav-
age of MAPKKs by LT is an important factor reducing the
intensity of signaling.
Anthrax LT and hemolytic factors compromise epithelial 
barrier permeability
After our findings demonstrated the fact of accelerated
Synd shedding, it was important to test if the latter is
accompanied by changes in barrier permeability. We used
a primary culture of human small airway epithelial cells
(HSAECs) grown on collagen-coated membranes with the
pores permeable to Dextran Blue 2000, which was used as
an indicator of barrier integrity [35]. The membranes sep-
arated the lower and the upper chambers of the culture
wells, thus mimicking the barrier represented in the lower
airways of the lung. The cells were challenged by adding
AnlO, ClnA or LT in the upper chambers for 4 h. After
treatment, Blue Dextran 2000 was added to the upper
chambers for 2 h. The changes in barrier permeability
were evaluated by measuring the optical absorbance of
Blue Dextran 2000 in the lower chambers, in comparison
with untreated cells. Fig. 7 shows that the AnlO and ClnA
cause intensive shedding of Synd1. In these experimental
conditions the LT challenge does not induce shedding and
therefore serves as a negative control. The effect of LT
becomes detectable only after the 24 h (data not shown).
In general, the HSAECs display the pattern of sensitivity to
AnlO, ClnA and LT similar to that of the NMuMG cells. As
expected, the treatment with AnlO and ClnA causes a
strong increase in barrier permeability (Fig. 7B) correlat-
ing with shedding. This suggests a possible causal rela-
tionship between the two processes, which needs to be
elaborated in further studies.
Anthrax infection in mice is accompanied by acceleration 
of Synd1 shedding
The experiments with recombinant proteins described
above suggested that Synd shedding could also take place
during anthrax systemic infectious process. To confirm
this hypothesis the DBA/2 mice were challenged with B.
anthracis spores of the toxigenic Sterne strain intraperito-
neally as described before [36]. Blood samples were
drawn, and serum was tested similar to culture superna-
tants of protein-treated cells using immunoblot with the
antibody against Synd1 core protein. The assay shows a
several-fold increase in the amount of shed Synd1 on the
Shedding of Synd1 into culture supernatants (A) and changes in barrier permeability (B) for HSAECs treated with the hemolytic  proteins and LT Figure 7
Shedding of Synd1 into culture supernatants (A) and changes in barrier permeability (B) for HSAECs treated with the hemolytic 
proteins and LT. The cells initially confluent on a 12 mm insert (Costar, 3.0 µm pores) were treated with 1 µg/ml of each pro-
tein for 4 h in 1% FCS media. After treatment the change in barrier permeability was tested as increase in the absorbance of 
Blue Dextran 2000 added for 2 h to the culture media in the top chamber and detected in the lower chamber, in comparison 
with untreated cells. Error bars represent 95% confidence intervals; 3 culture plate wells were used for each measurement.
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next day post challenge (Fig. 8A). ELISA protocol with the
same antibody demonstrates similar results, when diluted
serum samples are used to coat the assay plate wells (Fig.
8B). A high level of circulating ectodomain is sustained
until two days post-infection. A calibration curve
obtained with a control serum spiked with different con-
centrations of recombinant Synd1 allows estimate that
average blood Synd1 concentration at day 1 post chal-
lenge is increased by 18 µg/ml.
In the conditions of the experiment, about 50% of ani-
mals die at day 3, and all animals die by day 6 post chal-
lenge. The onset of death on day 3 is accompanied by a
decrease in the amount of released Synd1, which could be
explained by a number of mechanisms, such as degrada-
tion of syndecan core protein resulting in the loss of its
immunoreactivity with antibodies and a reduced reten-
tion of the protein on the surface of the assay membrane
or plate. In any case, the abnormal release of Synd1 into
circulation of infected mice directly indicates that the
pathological acceleration of Synd1 shedding takes place in
vivo at systemic level and is accompanied by the processes
of its biochemical turnover.
Discussion
Acceleration of ectodomain shedding represents a part of
an adaptive response of the host cells to different stress
factors and injury such as G protein-coupled receptor ago-
nists, growth factors, cytokines, osmotic stress, wounding
and phorbol ester activation [37-39]. However the func-
tional significance of the ectodomain shedding in micro-
bial pathology is uncertain: it could either promote
pathogenesis, cellular defenses or both. Microbial mem-
brane-damaging factors and other toxins can disturb cell
homeostasis and serve as strong inducers of stress pro-
ceeding through activation of signaling pathways ulti-
mately resulting in cytoskeletal rearrangements and
increase in barrier permeability [40]. Although the
cytoskeletal rearrangements and Synd1 ectodomain shed-
ding are closely interconnected [6,41], a direct link
between stress response, Synd1 ectodomain shedding and
barrier dysfunction has never been demonstrated for bac-
terial toxins.
Initial evidence that B. anthracis toxins can disrupt host
epithelial and endothelial barriers is available from early
anthrax publications. For example, Smith et al. [42] using
LT produced in vivo identified vascular damage and renal
failure as a consequence of its activity, while Smith and
Stoner [20] demonstrated that LT induced an increase in
vascular permeability. These observations agree with the
fact that the most damaged organs in the infectious proc-
ess are the ones with high epithelial and endothelial cell
content such as spleen, lungs, liver, renal system, vascula-
ture of blood and lymphatic vessels. A recent report by
Warfel  et al. [21] confirmed that LT can increase the
endothelial barrier dysfunction independent of necrosis
or apoptosis. The LT preparations used in early studies
were crude, so we took into account a possibility that
pathogenic factors other than LT could have played role in
the observed effects. A spectrum of these factors includes
(but may not be limited to) cytolytic lipases and pore-
forming toxins [13,43], and proteases of different specifi-
city [14,36].
Our experiments demonstrate that bacterial secreted fac-
tors, such as pore-forming toxin AnlO, and cytolytic
lipases ClnA and AnlB accelerate the normal process of
host cell Synd1 and E-cadherin ectodomain shedding,
which is as a proteolytic mechanism of releasing them in
Synd1 content in sera of mice challenged with 30 LD50 of Sterne strain spores intraperitoneally Figure 8
Synd1 content in sera of mice challenged with 30 LD50 of Sterne strain spores intraperitoneally. The serum samples were 
either dot-blotted in duplicates onto membrane (A) or were used to cover wells of the ELISA plate (B) for immunodetection 
of Synd1 with antibody 281-2. Graphs represent average fold increases over control. In (A), two mice were used at the day of 
challenge, three mice at each day 1 and 2, and two mice at day 3. In (B), seven mice were used at each of the days 0, 1 and 2, 
and three mice at day 3. A calibration concentration-response curve obtained by triplicate measurements of control serum 
spiked with recombinant Synd1 is shown in (C). The bars indicate 95% confidence intervals. *P < 0.05, **P < 0.01.
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a soluble form [4]. The effects of AnlO and AnlB are simi-
lar to what has been previously reported for their bio-
chemical analogs, staphylococcal α- and β-toxins,
respectively, in a similar concentration range [3]. We fur-
ther show that the process of Synd1 shedding is accompa-
nied by loss of epithelial barrier integrity of HSAECs in
culture. The abnormal level of shed Synd1 in the blood of
spore-challenged mice suggests that anthrax secreted fac-
tors could compromise epithelial barrier integrity at the
early stages of the disease.
The full spectrum of proteins shed in anthrax requires fur-
ther studies. Our preliminary data (not shown) indicate
that different combinations of shedding factors could pro-
duce synergictic effects. Biologically relevant concentra-
tions of anthrax shedding inducers in tissues, organs and
body fluids are unknown, and therefore the assessment of
each protein's contribution to ectodomain shedding in
vivo is currently impossible, but the capacity of B. anthracis
to produce hemolytic proteins, in addition to LT, has been
demonstrated in both aerobic and anaerobic culture con-
ditions [13,43,44]. The antibodies against these proteins
are also detectable in serum of mice challenged with B.
anthracis (Sterne) spores (data not shown). In our experi-
mental conditions the release of Synd1 and E-cadherin
takes place within several hours, and high levels of shed
Synds are detectable after 24 hours post infection with
spores (we have not tested earlier time points). This obser-
vation opens a possibility of using shed ectodomain
release into circulation for early detection of the anthrax
infectious process. Maximal Synd release coincides in
time with the appearance of bacteria in the spleens of
challenged animals tested in our previous experiments
[45]. Bacteria became detectable in the spleens at approx-
imately 16 h post infection, reached maximum numbers
at about 24 h and then declined before death.
Normally, ES is mediated by metalloproteinases, which
are collectively called sheddases or secretases. Our data
agree with the host sheddase modulation mechanism
demonstrated by others [3,5,38], because metalloprotein-
ase inhibitors such as galardin and phosphoramidon
reduce shedding induced by AnlO (data not shown),
which has no enzymatic activity on its own. Other anthrax
proteins, ClnA and AnlB are not proteases, and therefore
cannot shed Synd1 by direct proteolysis on the cell sur-
face. LT is a metalloprotease but induction of Synd1 shed-
ding requires LT delivery into the host cell, in agreement
with the extracellular cleavage of the Synd1 core protein
by cellular sheddase. The fact that proteins of an abso-
lutely different nature, such as proteases and lipases of dis-
tinct enzymatic specificities along with pore-forming
toxins possessing no catalytic activity, display similar
effects with regard to Synd1 shedding indicates activation
of a common intracellular mechanism by diverse extracel-
lular signals. Indeed, the activity of piceatannol against
shedding by all tested inducers suggests that cytoplasmic
Syk PTK serves as the common point of convergence. This
mechanism however retains a certain level of specificity
judging by the fact that neither PA nor LF induces shed-
ding.
The MAPK-mediated pathways have been previously
implicated in receptor-induced ectodomain shedding [5].
It has also been reported that AnlO stimulated the p38 sig-
naling in macrophages [34]. Our data show that the
inhibitors of ERK1/2 (PD98059) and p38 (SB202190)
decrease the AnlO- and LT-induced shedding. This effect
agrees with the mechanism recently discovered for the
hydrogen peroxide-stimulated cytoskeletal reorganization
in endothelial cells [46]. It has been shown that both of
the above inhibitors attenuated MAPK-mediated activa-
tion of the small heat shock protein Hsp27 downstream
from ERK1/2 and p38. This protein is responsible for the
actin stress fiber polymerization, which accompanies
Synd ectodomain shedding [41,47,48]. We however can-
not conclude which of the MAPK pathways plays a pre-
dominant role in shedding.
Currently available data suggest that the p38 pathway
defends against bacterial pore-forming toxins in vivo and
in vitro [49], therefore the p38-mediated shedding could
represent a protective cell response to stress (unless it
reaches a pathological proportion). In agreement with
this, Kevil et al. [50] reported that p38 inhibitor attenu-
ated the oxidant stress fiber formation and prevented gen-
eration of gaps between endothelial cells. Warfel et al. [21]
found that p38 inhibitor increased the endothelial barrier
resistance, although concluded that this effect was some-
what paradoxical given the ability of LT, as known inhib-
itor of MAPK signaling, to decrease barrier resistance. We
suggest that LT plays a dual role upon interaction with the
host cells by inducing both the cellular stress and the inhi-
bition of MAPK activation. The intricate combination of
both processes results in the reduction of the transient
stress signal, which nevertheless remains sufficient for the
induction of shedding but reduces the potency of LT as
shedding inducer. In support of this, our data show that
LT induces small but detectable activation of p38 even at
high LT concentration. In contrast to LT the pretreatment
of cells with the effective p38 inhibitor is expected to com-
pletely block the stress signal and the consequent shed-
ding. Transient p38 activation has never been reported in
connection with LT activity although LT-induced ERK1/2
activation has recently been described as toxin-induced LT
resistance in macrophages [51] in a lower concentration
range compared to our experiments.BMC Microbiology 2006, 6:8 http://www.biomedcentral.com/1471-2180/6/8
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Conclusion
Our findings provide additional insights into the studies
of B. anthracis virulence factors, such as LT and hemolytic
proteins, at cellular and organism levels, where shedding
has to be taken into account as a new anthrax pathogenic
mechanism. It could rapidly change cell surface properties
and increase barrier permeability by the concerted effect
of several pathogenic factors contributing to dissemina-
tion of infection, hemorrhages and edema. Shedding gen-
erates biologically active ectodomains that can function as
paracrine or autocrine effectors [8]. The shed soluble pro-
teoglycans are highly hydrated and this effect is expected
to exacerbate edema by causing influx of water into the
intercellular space. It has already been shown that shed
Synd1 is toxic to mice [52], and that inoculation of Synd1
ectodomain restored sensitivity of Synd-/- mice to P. aeru-
ginosa [2]. These findings suggest high pathological signif-
icance of Synd shedding in the anthrax infectious process,
which needs to be further addressed in animal experi-
ments.
Methods
Inhibitors, reagents and isolated proteins
NMuMG epithelial cells (CRL-1636) were from ATCC
(Manassas, VA), human lung epithelial cells (HSAEC)
were from Cambrex, Inc. (Walkersville, MD). DMEM
media was from ATCC (Manassas, VA), other cell culture
reagents were from Cellgro (Herndon, VA). Galardin, tyr-
phostin A25, piceatannol, suramin, SB202190, PD98059,
JNK inhibitor II and PP2 were from Calbiochem (Darm-
stadt, Germany). Anti-human Synd1 antibody clone Mi15
and rat anti-mouse Synd1 (clone 281-2) were from BD
Biosciences (San Diego, CA). Antibody against total and
double phosphorylated p38 (Thr180/Tyr182), ERK
(Thr202/Tyr204) and JNK (Thr183/Tyr185) were from
Cell Signaling Technology (Beverly, MA). Hemolytic B.
anthracis proteins were expressed in E. coli, purified and
characterized as described before [13]. They are at least
95% homogeneous based on the results of SDS-PAGE
analyses. The phospatidyl choline-preferring phospholi-
pase C from B. cereus (cereolysin A) was purchased from
Sigma (MA) and was used without further purification.
Recombinant protective antigen (PA) and lethal factor
(LF) were purchased from List Biological Laboratories
(Campbell, CA). The endotoxin content of all proteins
was determined by Quantitative Chromatogenic LAL kit
(Cambrex, MD). Recombinant murine Synd1 expressed
in E. coli as a His6-tagged protein (>95% purity) was a gift
from Prof. Myung-Chul Chung (George Mason Univer-
sity, VA). The protein concentration was determined using
Bradford assay with BSA as a standard.
Activation of shedding in cultured cells
Human Small Airway Epithelial Cells, or HSAECs (Cam-
brex, Inc., Walkersville, MD), were grown in DMEM/F12
complete medium with 10% fetal calf serum (FCS,
Gibco). Before challenge the FCS content was reduced to
1%. NMuMG cells were grown up in Dulbecco's modified
Eagle's medium with 4.5 g/l glucose, 10 µg/ml insulin,
and 10% FCS. HSAECs were grown up in Ham's F12
media supplemented with non-essential aminoacids,
pyruvate,  β-mercaptoethanol and 10% FCS. Cells were
seeded in 96-well plates, cultured to 1 day post conflu-
ence, then stimulated with indicated proteins using
serum-free media from Cellgro (Herndon, VA) supple-
mented with 1% FCS. LT was used as a mixture of equal
amounts of PA and LF at total concentration of 1.0 µg/ml,
0.1 µg/ml, and 0.01 µg/ml. After stimulation, the plates
were spun down at 1,100 × g for 10 min and supernatant
was frozen at -20°C for further analyses. In control exper-
iments, a known inducer of Synd1 shedding, PMA (4α-
phorbol-12,13 didecanoate) in concentration 10 µM in
1% FCS media induced 4-fold increase in shed Synd-1
from NMuMG cells after 24 h incubation. In the same
conditions, endotoxin in concentration 10 ng/ml induced
neither significant shedding nor activation of p38 and
ERK1/2. Pre-treatment of AlnO (1 µg/ml) with polymyxin
(50 µg/ml) had no effect on the amount of shed Synd1
and the p38 or ERK1/2 phosphorylation. Endotoxin con-
tamination from added proteins in shedding experiments
did not exceed 5 ng per ml of culture medium.
Dot Blot Assays
Supernatant from treated cells (100 µl) was added to 1 ml
of acidification buffer (150 mM NaCl, 50 mM NaOAc,
0.1% Tween-20, pH 4.5). Immobilon NY+ membrane (9
× 12 cm, Millipore) was prepared by first soaking it in
acidification buffer. Bio-Dot  microfiltration apparatus
(Bio-Rad, CA) was used for all syndecan dot blots. The
sample wells were re-saturated with 100 µl of acidification
to prevent drying of the membrane. 400 µl of sample solu-
tion (in acidification buffer) was used per well on the
apparatus. First the sample was kept in the wells on top of
the membrane for 3 min and then it was drawn through
the filter/membrane for another 3 min. The wells were
rinsed twice with 400 µl of acidification buffer. The mem-
brane was taken out, rinsed twice for 5 min in acidifica-
tion buffer and blocked with 3% powdered milk in buffer
#2 (150 mM NaCl, 10 mM Tris-HCl, pH 7.4) for 1 h. The
membrane was then incubated with rat anti-mouse Synd1
antibody at a dilution of 1:1000 in 3% milk in buffer #3
(150 mM NaCl, 10 mM Tris-HCl, 0.3% Tween-20, pH
7.4) for 2 h on a platform shaker at room temperature. For
the cells of human origin the antibody against human
Synd1 has been used in a dilution 1:2000. The membrane
was then washed with buffer #3 three times for 5 min and
incubated with goat anti-rat HRP-conjugated secondary
antibody at a dilution of 1:7500 for murine Synd1 blot, or
with goat anti-mouse HRP-conjugated polyclonal anti-
body at 1:1000 for the heparan sulfate or human Synd1BMC Microbiology 2006, 6:8 http://www.biomedcentral.com/1471-2180/6/8
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blots for 1 h at room temperature. The membranes were
then washed again three times for 5 min with buffer #3.
All membranes were developed using ECL Plus Western
Blotting Detection kit (Amersham Biosciences, NJ) and
Kodak BioMax Light Film (Sigma, MO). The results were
quantified by scanning the exposed film, and evaluating
the intensity of exposed dots by software AlphaEase FC
(Alpha Innotech, San Leandro, CA). Results were
expressed as amount of Synd shed in relative absorbance
units (AU) using a calibration curve generated by two-fold
dilutions of culture supernatants from mouse or human
epithelial cells treated with AnlO. The absolute amounts
of shed ectodomain varied between experiments, presum-
ably because of the sensitivity of shedding to small varia-
tions in treatment conditions noticed previously [5]. Each
AU measurement represents the mean and the 95% confi-
dence intervals calculated using the Student t-test.
Lactate dehydrogenase (LDH) release from treated cells
The LDH activity in the culture medium was measured as
index of cytolysis using a spectrophotometric assay with
pyruvate and NADH as substrates according to the manu-
facturer's protocol (Roche Applied Science, Germany)
using 10 µl samples of culture medium from treated or
untreated cells. To determine total intracellular LDH activ-
ity the untreated cells were lysed with 1% Triton X-100,
and the assay was performed simultaneously with the test
culture medium samples. The fraction of lysed cells in par-
ticular treatment conditions was calculated as the LDH
release into the incubation medium relative to the total
LDH activity present in the epithelial cells before treat-
ment. Each measurement was done in triplicate. The
mean and the 95% confidence intervals were calculated
using the Student t-test.
Western blot of Synd1 after heparanase and 
chondroitinase digestion
Confluent NMuMG cells grown as described above were
put in 1% FCS media with either ClnA, Anl B, Anl O or LT
for 24 h. After 24 h, the floating cells were removed from
supernatant by centrifugation, and proteoglycans in con-
ditioned media were precipitated twice with 4 volumes of
95% ethanol containing 3% potassium acetate. Pellet was
resuspended in 100 µM Tris-HCl, pH 8.0 containing 0.1%
Triton X-100, 5 µM EDTA, and 1 mM phenylmethylsulfo-
nyl fluoride. Half of each sample was incubated with both
10 mU/ml of heparan sulfate lyase and 25 mU/ml chon-
droitin sulfate lyase ABC (Seikagaku America Inc., Rock-
ville, MD) for 5 h at 37°C. A fresh portion of enzymes was
added after 2.5 h of incubation. Enzyme-treated samples
(equivalent to 0.5 ml of conditioned media) were sub-
jected to SDS-PAGE (3.5 to 20% gradient gel) and electro-
transferred to Immobilon-N+ membranes (Bio-Rad, CA),
which were processed as described above for the dot-blot
immunoassay.
Syndecan-1 and E-cadherin immunostaining
NMuMG cells were grown to confluence on glass slides
(BD Falcon and BD BioCoat) for 5 days and then chal-
lenged with indicated components. Cells were fixed for 10
min with methanol, washed 3 times with PBS, and then
blocked for 20 min with 1% BSA in PBS. After washing
with PBS, FITC-labeled murine monoclonal anti-mouse
E-cadherin or anti-mouse Synd1 monoclonal antibodies
(both from BD Transduction Laboratories) were used for
1 h staining in a dark, after which the slides were washed
with PBS, mounted and examined under fluorescence
microscope with appropriate filters. Vectashield mount-
ing medium included diamidino phenyl indole (DAPI)
for nuclear staining. According to the manufacturer, the
anti-mouse E-cadherin antibody cross-reacts with human
E-cadherin.
Analysis of mouse sera after challenge with B. anthracis 
spores
The 9 week old mice (DBA/2 from Taconic, Germantown,
NY) were challenged intraperitoneally with 1 × 107 spores
of  B. anthracis non-encapsulated Sterne strain 34F2
[pXO1+, pXO2-] obtained from the Colorado Serum
Company (Boulder, CO). The 50% lethaldose of 3 × 106
spores (LD50) by the inraperitoneal (i.p.) route was estab-
lished earlier [22]. Mice were anesthetized by intraperito-
neal injection of Avertin (2,2,2 tribromethanol, Aldrich)
at 24 h time points and were bled by cardiac puncture.
Serum sample (20 µl) from each mouse was analyzed sep-
arately in triplicate with dot blot as described above for
cell culture supernatants.
For the ELISA assay of Synd1, serum from each mice (2.5
µl) was diluted in 200 µl of phosphate buffered saline
(PBS), 0.5 mM EDTA, 0.1 mM PMSF, 0.1% NP-40 (Pierce)
and used to coat wells of the Nunc Maxisorp™ plates (eBi-
osciences) overnight at 4°C. After incubation, the plates
were washed 3 times with 200 µl per well of PBS, 0.1%
Tween-20 and blocked for 1 h at 4°C with 200 µl per well
of PBS plus 1% BSA (Sigma). Plates were incubated in 100
µl per well of fresh blocking solution plus 1:1000 dilution
of rat anti-mouse Synd1 antibody 281-2 (BD Biosciences)
for 2 h at 4°C, washed 5 times with 200 µl per well of PBS,
0.1% Tween-20, and finally incubated at room tempera-
ture for 1 h with 100 µl per well of goat anti-rat HRP-con-
jugated secondary antibody (Jackson Immunoresearch)
diluted 1:7500 with blocking solution. After incubation,
plates were washed 5 times with 300 µl per well of PBS,
0.3% Tween-20 and developed using tetramethyl benzi-
dine reagent (Beckman Coulter) added to all wells and
incubated at room temperature for 30 min. Absorbance
was detected at 450/570 nm using µQuant plate reader
(Bio-Tek Instruments). The average absorbance calculated
for each treatment group was corrected for the average
absorbance of the control wells without serum, and theBMC Microbiology 2006, 6:8 http://www.biomedcentral.com/1471-2180/6/8
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results were presented as a fold change relative to the
untreated group value. The concentration-response curve
was obtained using naïve mouse serum from the unchal-
lenged control group spiked with serial dilutions of
recombinant murine Synd1. The curve shows a linear
slope (R2 = 0.998) in the tested interval of spiked Synd1
concentrations (0 to 22 µg/ml). It allows estimate the
Synd1 release due to infection, however the amount of
Synd1 present in normal serum cannot be determined.
Epithelial barrier permeability studies
HSAECs were grown on commercially available Costar
inserts (Corning, NY) consisting of 12 mm permeable
PTFE membranes with a pore size of 3.0 µm, and coated
by the manufacturer with equal mixtures of Type I and
Type III Collagen. Cells were seeded at concentrations of
1 × 105 cell/ml and allowed to grow till confluence in
DMEM/F12 complete medium with 10% FCS. Before
challenge the FCS content was reduced to 1%. Epithelial
barrier permeability to small molecules was evaluated
after the cells were treated with shedding inducers by the
addition of Blue Dextran 2000 (Sigma, MO) to the upper
chamber of the inserts above the epithelial cells, incuba-
tion for 2 h, and then measuring the absorbance of
medium in the lower chamber at 600 nm. The absorbance
values were normalized relative to the untreated cells con-
trol.
Statistical analyses
Data are presented as means ± confidence intervals for
replicate experiments (n ≥ 3) unless indicated otherwise.
Unpaired two-tailed Student's t test was used for statistical
analyses, and confidence intervals were calculated for P =
0.05.
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